Meeting
2012 Gastrointestinal Cancers Symposium
Efficacy of vemurafenib, a selective BRAFV600E inhibitor, in combination with a MEK inhibitor in BRAFV600E colorectal cancer models.
Authors
Brian Higgins
Pharma Research and Early Development, Hoffmann-La Roche Inc., Nutley, NJ
Brian Higgins , Kenneth Daniel Kolinsky , Hong Yang , Min Jung Kim , Jia Kui Li , Zenaida Go , Kathryn Packman , Gideon Bollag , Fei Su
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 30, 2012 (suppl 4; abstr 488)
DOI
10.1200/jco.2012.30.4_suppl.488
Abstract #
488
Poster Bd #
C11
Abstract Disclosures
Similar Posters
Poster
2012 Gastrointestinal Cancers Symposium
Efficacy of vemurafenib (V) a selective V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.
First Author: Brian Higgins
Poster
2014 ASCO Annual Meeting
Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models.
First Author: LI Liu
Poster
2022 ASCO Annual Meeting
Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm.
First Author: Shaji Kumar
Poster
2020 ASCO Virtual Scientific Program
Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.
First Author: Sanne Huijberts